Changes in serum phosphorus, calcium and alkaline phosphatase due to sucralfate.
We report on the results of the clinical trial, where the effects of sucralfate on the serum phosphorus, calcium and alkaline phosphatase in 30 patients with chronic renal failure on intermittent hemodialysis were examined. After 14 days of treatment with sucralfate (1 gram four times daily), we found a significant reduction in serum phosphorus and alkaline phosphatase and an increase in serum calcium. On the basis of its proven hypophosphatemic and ulcer-healing effects, sucralfate can be recommended in treatment of hyperphosphatemia and secondary hyperparathyroidism in chronic renal failure. Serum phosphorus should be checked routinely in patients treated with sucralfate for the peptic ulcer disease.
D000469:Alkaline Phosphatase / Q000097:blood*; D000535:Aluminum / Q000009:adverse effects* / Q000627:therapeutic use; D002118:Calcium / Q000097:blood*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy; D008297:Male; D010758:Phosphorus / Q000097:blood*; D013392:Sucralfate
D010758:Phosphorus; D013392:Sucralfate; D000535:Aluminum; D000469:Alkaline Phosphatase; D002118:Calcium